Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons - Poll - MDSpire

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

  • By

  • Naseema Gangat

  • Ayalew Tefferi

  • May 7, 2025

  • 0 min

Share

Original Source(s)

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

  • by Naseema Gangat, Ayalew Tefferi

  • May 7, 2025

Related Content

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

Molecular Identification of HTLV-1 and HCV Infections in Sickle Cell Disease Patients Undergoing Multiple Transfusions in Kinshasa: A Case Study of CMMASS

The patients demanding unvaccinated blood transfusions